Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

8.040 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 8.040
Bid (Size) 8.050 (1)
Ask (Size) 8.520 (5)
Prev. Close 8.040
Today's Range 8.040 - 8.040
52wk Range 6.575 - 22.93
Shares Outstanding 75,480,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for 89bio
Via Benzinga
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with  
Via Benzinga

Performance

YTD
-32.83%
-32.83%
1 Month
+8.65%
+8.65%
3 Month
-53.09%
-53.09%
6 Month
-57.42%
-57.42%
1 Year
+0.50%
+0.50%

More News

Read More
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
From 89bio, Inc.
Via GlobeNewswire
Analyst Expectations for 89bio's Future
Via Benzinga
The Latest Analyst Ratings for 89bio
Via Benzinga
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
Why Shares of 89bio Plummeted on Tuesday
Via The Motley Fool
Akero Therapeutics' Disappointing NASH Data Drags Its Rival
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Analyst Ratings for 89bio
Via Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Akero Therapeutics Stock Is Crashing Today
Via The Motley Fool
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Gain; PepsiCo Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the 2023 Cantor Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From 89bio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.